Janus Henderson Group
LJPC

Janus Henderson Group’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Janus Henderson Group’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-846,182
Closed -$25.2M – 1384
2017
Q2 		$25.2M Buy
+846,182
New +$24.2M 0.02% 686

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group's LJPC Position: Q3 2017 in Review

Janus Henderson Group sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2017, closing a stake of 846,182 shares — an estimated $25.2M sold.

Janus Henderson Group first reported a position in LJPC in Q2 2017 and held it in 1 quarter. The position peaked at $25.2M in Q2 2017. 95 funds tracked by Wall St. Rank hold LJPC as of Q3 2017.

  • Janus Henderson Group reported no remaining La Jolla Pharmaceutical Company position as of Q3 2017 after selling out during the quarter.
  • Janus Henderson Group sold 846,182 La Jolla Pharmaceutical Company shares in Q3 2017, an estimated $25.2M.
  • Janus Henderson Group first reported a position in La Jolla Pharmaceutical Company in Q2 2017 and held it in 1 quarter.
  • Janus Henderson Group's La Jolla Pharmaceutical Company position peaked at $25.2M in Q2 2017.
  • 95 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2017.

Based on Janus Henderson Group's 13F filing for Q3 2017, filed 14 Nov 2017.